– UK, London – Smith & Nephew Plc (LSE:SN, NYSE:SNN), the global medical technology business, announces that Angie Risley is to join its Board as Non-Executive Director and Chairman Elect of the Remuneration Committee on 18 September 2017. It is intended that Angie Risley will assume the role of Chairman of the Remuneration Committee at the Annual General Meeting to be held in 2018 on the retirement of Joseph Papa from the Board.
Roberto Quarta, Chairman of Smith & Nephew, commented: “Angie Risley is a well-regarded FTSE 100 Human Resources Director and a proven Non-Executive Director and Remuneration Committee Chairman with experience of a wide range of different sectors, including a regulated environment. I am certain that she will be a great addition to our Board and provide effective leadership to our Remuneration Committee when Joe Papa steps down next year.”
Angie Risley is currently Group HR Director of J Sainsbury plc and has previously held similar senior roles at Whitbread PLC and Lloyds Banking Group plc. She is also a Non-Executive Director of Sainsbury’s Bank Board. She is currently Chairman of the Remuneration Committee of Serco Plc where she will shortly be stepping down. Previously, she has held similar positions at Arriva plc and Biffa plc.
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were almost $4.7 billion. Smith & Nephew is a member of the FTSE 100 (LSE:SN, NYSE:SNN).
For more information : http://www.smith-nephew.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
